Related Experiment Video
Updated: Jun 9, 2026

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies
Published on: July 19, 2007
The Orphan Drug Act and the development of stem cell-based products for rare diseases
Scott N Freeman1, Kathryn A Burke, Menfo A Imoisili
1Office of Orphan Products Development, Office of Special Medical Programs, Office of the Commissioner, United States Food and Drug Administration, Silver Spring, MD 20993, USA.
Abstract:
The Orphan Drug Act encourages the development of products for rare diseases and conditions. Many conditions that stand to benefit from stem cell-based products are rare diseases. We address the Orphan Drug Act in relation to the development of stem cell-based products.
Related Concept Videos
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Regulation
iPS Cell Differentiation
Drug Products: Biologics, Biosimilars and Interchangeables
Stem Cell Culture
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

